The Safety and Efficacy of Intravitreal Topotecan for the Treatment of Proliferative Vitreoretinopathy

PHASE1Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 1, 2025

Primary Completion Date

March 1, 2026

Study Completion Date

March 1, 2026

Conditions

Proliferative VitreoretinopathyProliferative Vitreo-RetinopathyRhegmatogenous Retinal Detachment

Interventions

DRUG

Topotecan

20 micrograms of intravitreal topotecan given in a 1 cc tuberculin syringe at a concentration of 20 mcg/20mcL.

All Listed Sponsors

lead

Massachusetts Eye and Ear Infirmary

OTHER